Thermo Fisher Scientific’s organic revenues increased 3% in the quarter. Credit: Thermo Fisher Scientific Inc.

Thermo Fisher Scientific has reported an 18% increase in revenue to $10.97bn in the second quarter of the year, compared to $9.27bn in the same quarter last year.

Its organic revenues in the reported quarter rose 3% and acquisitions revenue increased by 19%, while currency translation lowered revenue by 4%.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Core organic revenue growth stood at 13%, while $0.63bn of Covid-19 testing revenue was reported for the quarter.

During the quarter, the GAAP diluted earnings per share (EPS) attributable to Thermo Fisher was $4.22, compared to $4.61 in the same quarter last year.

The company’s GAAP operating income was $2bn, versus $2.16bn in the year-ago quarter.

In this quarter, new products launched by Thermo Fisher Scientific include the Gibco CTS TrueCut Cas9 Protein and Phadia 2500+ series of instruments.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It also introduced the Thermo Scientific AccelerOme Automated Sample Preparation Platform and Thermo Scientific Direct Mass Technology.

The company has expanded its cell culture media capacity in Grand Island, New York, US, to support its research and drug production applications.

Thermo Fisher Scientific chairman, president and CEO Marc Casper said: “We delivered another quarter of outstanding financial performance.

“Our proven growth strategy and PPI Business System enabled us to deliver exceptional results across our business and we continue to see the benefit of our strategic investments to enhance our unique customer value proposition.

“The integration of our clinical research business is going very well, the business is performing at a high level and the outlook for long-term synergies is very compelling.”

Earlier this month, the company introduced its CE-IVD-marked molecular Applied Biosystems TaqPath Respiratory Viral Select Panel.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact